NCT06419673

Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer

Name: Clinical Trial NCT06419673
Creator: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Keywords: Cervical Cancer, Serplulimab, Phase 2, drug, clinical trial, China

Induced and Concurrent Serplulimab Plus Chemoradiotherapy Followed by Toripalimab Maintenance Therapy for Stage III-IVA Cervical Cancer: a Prospective, Multicenter, Randomized, Open Controlled Clinical Trial

Cancer Institute and Hospital, Chinese Academy of Medical Sciences·Phase 2·ClinicalTrials.gov·drugRecruitment Completed

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Cervical Cancer
Drug/Device/Intervention: Serplulimab
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Location: Beijing, China

Timeline & enrollment

Phase: Phase 2
Start date: May 01, 2024
End date: May 31, 2028
Enrollment: 240 participants

Primary outcome

Progression-Free Survival(PFS) at Month 36

Summary

This study is a prospective, multicenter, randomized, open controlled clinical trial aimed at evaluating the effectiveness and safety of serplulimab plus chemoradiotherapy in FIGO 2018 stage III or IVA cervical squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma patients who have not received prior treatment.

ICD-10 classifications

Severe cervical dysplasia, not elsewhere classifiedMild cervical dysplasiaModerate cervical dysplasiaCarcinoma in situ: Cervix, unspecifiedCervical root disorders, not elsewhere classified

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06419673
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06419673 through Pure Global AI's free database. This Phase 2 trial is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences and is currently Recruitment Completed. The study focuses on Cervical Cancer. Target enrollment is 240 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.